Boston Scientific Corporation $BSX Holdings Boosted by Alliance Wealth Advisors LLC UT

Alliance Wealth Advisors LLC UT grew its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 207.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,560 shares of the medical equipment provider’s stock after purchasing an additional 11,178 shares during the quarter. Alliance Wealth Advisors LLC UT’s holdings in Boston Scientific were worth $1,617,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FWL Investment Management LLC bought a new stake in Boston Scientific in the second quarter valued at $26,000. Steph & Co. bought a new position in Boston Scientific in the 3rd quarter worth about $25,000. Murphy & Mullick Capital Management Corp increased its stake in shares of Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the period. Financial Consulate Inc. acquired a new position in shares of Boston Scientific during the third quarter worth approximately $25,000. Finally, United Community Bank boosted its position in shares of Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 147 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on BSX shares. Canaccord Genuity Group cut their target price on Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a research note on Tuesday. National Bank Financial set a $115.00 price target on Boston Scientific in a report on Monday, February 2nd. Morgan Stanley reduced their price objective on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Royal Bank Of Canada decreased their target price on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Finally, BTIG Research restated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $108.36.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. 0.50% of the stock is currently owned by insiders.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $74.54 on Friday. The company has a market capitalization of $110.61 billion, a PE ratio of 38.42, a price-to-earnings-growth ratio of 1.03 and a beta of 0.67. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.96 and a current ratio of 1.62. The stock has a fifty day moving average of $89.23 and a 200-day moving average of $96.57. Boston Scientific Corporation has a one year low of $72.69 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period in the previous year, the firm earned $0.70 earnings per share. Boston Scientific’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.